Comparing Lenvatinib/Pembrolizumab with Atezolizumab/Bevacizumab in Unresectable Hepatocellular Carcinoma: A Real-World Experience with Propensity Score Matching Analysis
Our findings suggest that L+P and A+B exhibit comparable efficacy and safety profiles in real-world settings.
Authors
- Ching‐Ting Wang
- Yi‐Chung Hsieh (ORCID: https://orcid.org/0000-0002-1191-4399)
- Chen‐Chun Lin (ORCID: https://orcid.org/0000-0002-2907-2679)
- Po‐Ting Lin (ORCID: https://orcid.org/0000-0002-7486-8908)
- Wei Teng (ORCID: https://orcid.org/0000-0001-5663-1440)
- Chun‐Yen Lin (ORCID: https://orcid.org/0000-0003-3007-3190)
- Pei‐Mei Chai
- Wei‐Ting Chen (ORCID: https://orcid.org/0000-0001-8246-0219)
- Chung‐Wei Su (ORCID: https://orcid.org/0000-0003-2778-3618)
- Shi‐Ming Lin (ORCID: https://orcid.org/0000-0001-7527-6181)
- Yu-Chun Hsu
Institutions
- Chang Gung University (TW)
- Chang Gung Memorial Hospital (TW)
Publication Details
- Journal
- Cancers
- Published
- 2024-10-12
- DOI
- https://doi.org/10.3390/cancers16203458
- Citations
- 5
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.85
Funders
- National Science Council
- Chang Gung Medical Foundation